A Phase 3 interventional study of SB16 (Proposed Denosumab Biosimilar) and Prolia® (Denosumab) in Postmenopausal Osteoporosis, sponsored by Samsung Bioepis Co., Ltd.. Completed at 5 sites in Poland. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Samsung Bioepis Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Osteoporosis, Postmenopausal with a site in Poland — none open to participants now, 2 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · Poland.
Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, this one is the 24th largest by enrollment, is the only one that started in 2020, is one of 27 in phase 3, and was the 27th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →None of the 36 studies in Osteoporosis, Postmenopausal with a site in Poland is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 457 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 543 across the 36 interventional studies. Of the 34 that completed or were terminated, 29 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 36 have an industry lead sponsor. The 10 most frequent:
Samsung Bioepis Co., Ltd. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Samsung Bioepis Co., Ltd. has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies in Osteoporosis, Postmenopausal with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577935Angitia BiopharmaceuticalsA Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis.
Subjects will be randomised in a 1:1 ratio to receive either SB16 or Prolia®. At Month 12, subjects in Prolia® treatment group will be randomised again in a 1:1 ratio to either continue on Prolia® treatment or be transitioned to SB16 treatment. Investigational product (60 mg in 1 mL of SB16 or Prolia®) will be given subcutaneously every 6 months up to Month 12, and the last assessment will be done at Month 18.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.
Drug: SB16 (Proposed Denosumab Biosimilar)
Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months. At Month 12, subjects in Prolia® treatment group will be re-randomised in a 1:1 ratio to either continue on Prolia® treatment or be transitioned to SB16 treatment. After re-randomisation, subjects transited to SB16 group will receive SB16, and subjects remaining in Prolia® group will continue to receive Prolia® at Month 12.
Drug: SB16 (Proposed Denosumab Biosimilar) · Drug: Prolia® (Denosumab)
Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months. At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously.
Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
Percent Change From Baseline in Lumbar Spine BMD at Month 12
Time frame: Baseline and Month 12
| Milestone | SB16 | Prolia | SB16+SB16 | Prolia+SB16 | Prolia+Prolia |
|---|---|---|---|---|---|
| Started | 225 | 232 | 0 | 0 | 0 |
| Completed | 206 | 201 | 0 | 0 | 0 |
| Not completed | 19 | 31 | 0 | 0 | 0 |
| Milestone | SB16 | Prolia | SB16+SB16 | Prolia+SB16 | Prolia+Prolia |
|---|---|---|---|---|---|
| Started | 0 | 0 | 206 | 100 | 101 |
| Completed | 0 | 0 | 206 | 99 | 99 |
| Not completed | 0 | 0 | 0 | 1 | 2 |
| %Change of BMD | SB16 | Prolia |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine BMD at Month 12 | 5.63 ± 0.250 | 5.30 ± 0.254 |
Collected over Overall Period (18 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SB16 | 0/225 (0%) | 12/225 (5.3%) | 116/225 (51.6%) |
| Prolia Overall | 0/231 (0%) | 11/231 (4.8%) | 107/231 (46.3%) |
| Prolia+SB16 | 0/100 (0%) | 5/100 (5%) | 46/100 (46%) |
| Prolia+Prolia | 0/101 (0%) | 3/101 (3%) | 49/101 (48.5%) |
| Event | SB16 | Prolia Overall | Prolia+SB16 | Prolia+Prolia |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/225 | 1/231 | 1/100 | 0/101 |
| Transient ischaemic attackNervous system disorders | 0/225 | 1/231 | 1/100 | 0/101 |
| NephrolithiasisRenal and urinary disorders | 0/225 | 1/231 | 1/100 | 0/101 |
| Urethral caruncleRenal and urinary disorders | 0/225 | 1/231 | 1/100 | 0/101 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/225 | 1/231 | 1/100 | 0/101 |
| General physical health deteriorationGeneral disorders | 0/225 | 1/231 | 0/100 | 1/101 |
| CataractEye disorders | 0/225 | 1/231 | 0/100 | 1/101 |
| Retinal detachmentEye disorders | 0/225 | 1/231 | 0/100 | 1/101 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | 0/225 | 1/231 | 0/100 | 1/101 |
| Intervertebral discitisInfections and infestations | 0/225 | 1/231 | 0/100 | 1/101 |
| Event | SB16 | Prolia Overall | Prolia+SB16 | Prolia+Prolia |
|---|---|---|---|---|
| HypocalcaemiaMetabolism and nutrition disorders | 23/225 | 27/231 | 11/100 | 13/101 |
| COVID-19Infections and infestations | 20/225 | 18/231 | 5/100 | 11/101 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/225 | 12/231 | 7/100 | 4/101 |
| NasopharyngitisInfections and infestations | 10/225 | 18/231 | 7/100 | 9/101 |
| HeadacheNervous system disorders | 17/225 | 13/231 | 8/100 | 5/101 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 16/225 | 7/231 | 2/100 | 5/101 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 4/225 | 7/231 | 6/100 | 0/101 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 11/225 | 9/231 | 6/100 | 3/101 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 11/225 | 11/231 | 5/100 | 6/101 |
| Upper respiratory tract infectionInfections and infestations | 13/225 | 12/231 | 3/100 | 5/101 |
| Age, Categorical(Participants) | SB16 | Prolia | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 89 | 95 | 184 |
| >=65 years | 136 | 137 | 273 |
| Age, Continuous(years) | SB16 | Prolia | Total |
|---|---|---|---|
| Mean | 66.5 ± 5.87 | 66.3 ± 6.03 | 66.4 ± 5.95 |
| Sex: Female, Male(Participants) | SB16 | Prolia | Total |
|---|---|---|---|
| Female | 225 | 232 | 457 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SB16 | Prolia | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 18 | 23 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 207 | 208 | 415 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2020 to primary completion in Jun 2022, 18 months.
Results were first posted in Jan 2025, 2 years 6 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 18 months is below that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osteoporosis, Postmenopausal →